Critically, CCT3833 mediates tumor regression in G12SKRAS-mutant NSCLC xenografts, so it could be considered for treatment of KRAS-mutant NSCLC patients who fail chemotherapy and/or immunotherapy. Here, KRAS is linked to neoplasm.